Press release
Nadrich & Cohen LLP Support's FDA-Mandated Vaginal Mesh Studies
The U.S. Food and Drug Administration has ordered transvaginal mesh implant manufacturers to conduct additional safety studies on these devices. Nadrich & Cohen LLP is currently offering free initial case evaluations to women in all 50 states who believe they were injured by a vaginal mesh implant.Los Angeles, CA, January 13, 2012 – Nadrich & Cohen LLP is pleased to announce that it supports the Food and Drug Administration’s recent call for additional safety testing of vaginal mesh devices. The order comes as the number of lawsuits filed against vaginal mesh manufacturers continues to mount.
The FDA sent requests to 33 mesh device manufacturers ordering them to conduct post-market surveillance studies of these products. Specifically, the FDA is asking the manufacturers to perform a three-year market survey to track side effects and the quality of life of patients who are implanted with one of these devices.
Vaginal mesh was approved to treat pelvic organ prolapse (POP) in 1996. This condition causes a weakening of the pelvic floor muscles, which can result in numerous side effects, including stress urinary incontinence. Concerns were raised over the safety of these devices after the FDA received numerous complaints from women who say the mesh implants caused pain, swelling and other side effects.
In July 2011, the FDA issued an updated safety communication advising women and health care professionals that the risks associated with vaginal mesh may outweigh the benefits. Despite the updated warning, no plans have been announced to recall any devices currently on the market.
Two of the biggest companies targeted by the FDA’s order are C.R. Bard, maker of Avaulta mesh, and Johnson & Johnson, maker of the Ethicon Gynecare mesh system. Both companies face multiple lawsuits from women who say they suffered serious injury after receiving one of the mesh implants.
If you or a loved one experienced severe pain, swelling, infection, tissue damage or other complications after receiving a vaginal mesh implant, you may complete a MedWatch form by visiting www.fda.gov. It is also recommended that you contact an experienced vaginal mesh attorney to discuss your legal rights.
Nadrich & Cohen LLP offers confidential, no-cost consultations to women across the country who believe they were harmed by a mesh device. Help is available by calling the firm’s injury hotline at 1-800-722-0765 or by completing an online case evaluation form at www.vaginalmeshlegalclaims.com.
Nadrich & Cohen LLP is a national law firm with offices in Los Angeles, Sacramento, San Diego and other cities throughout California. The firm specializes in handling mass tort actions and representing individuals in cases involving pharmaceutical companies, medical device makers and other product manufacturers. The firm is committed to achieving the best outcome possible in every case and has recovered over $200 million in settlements on behalf of its clients.
In addition to handling vaginal mesh claims, Nadrich & Cohen LLP is also investigating cases involving Accutane, Actos, Avandia, Fosamax, Paxil, Zoloft, DePuy ASR Hip Recall, Zimmer Hip Recall, Wright Conserve Hips, Yaz, Yasmin, Stevens-Johnson Syndrome, Benzene, Reflex Sympathy Dystrophy, Fen Phen and PPH, Depakote and Reglan.
The time you have to file an injury claim is limited, so it’s important to act as quickly as possible to protect your rights. Call 1-800-722-0765 today to speak with a qualified personal injury expert or visit www.personalinjurylawcal.com. All cases are accepted on a contingency basis and there is never a fee unless we recover monetary damages on your behalf.
Nadrich & Cohen LLP is a national law firm specializing in representing individuals who have been injured by defective medical devices, harmful prescription drugs, faulty products, car accidents, motorcycle accidents and dog bites. For more information, visit www.PersonalInjuryLawCal.com.
Jennifer Poole
National Client Intake Coordinator
Nadrich & Cohen LLP
12100 Wilshire Blvd.
Suite 1250
Los Angeles, CA 90025
800-718-4658
info@personalinjurylawcal.com
www.personalinjurylawcal.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Nadrich & Cohen LLP Support's FDA-Mandated Vaginal Mesh Studies here
News-ID: 207137 • Views: …
More Releases from Nadrich & Cohen LLP
Yaz Lawsuit Settlements Reach $142 Million
Nadrich & Cohen, LLP reports that Bayer is continuing to offer settlements to plaintiffs involved in federal Yaz side effects litigation.
Los Angeles, CA, April 27, 2012 – Nadrich & Cohen, LLP reports that German drug-maker Bayer AG has settled approximately 651 Yaz side effects lawsuits totaling $142 million. Earlier this month, it was reported that the drug-maker had reached settlements in approximately 500 cases filed by women who claimed…
Yaz, Yasmin to Get New Labels as FDA Warns of Blood Clot Risk
Nadrich & Cohen, LLP reports that Yaz and similar birth control pills are to receive updated warning labels advising patients of the risk for developing serious blood clots.
Los Angeles, CA, April 10, 2012 – National law firm Nadrich & Cohen, LLP has learned that the U.S. Food and Drug Administration has ordered Bayer to produce new warning labels for several of its oral contraceptives, including Yaz, Yasmin and Beyaz.…
FDA Schedules Advisory Panel Meeting to Discuss Metal Hip Safety
Nadrich & Cohen, LLP reports that the FDA has scheduled an advisory panel to discuss the safety of metal hip implants.
Los Angeles, CA, March 29, 2012 – National law firm Nadrich & Cohen, LLP has learned that the U.S. Food and Drug Administration has a scheduled an advisory panel meeting to discuss the safety of metal hip implants and all-metal hip resurfacing systems.
The two-day panel, which is expected…
Pradaxa Side Effects Lawsuits Filed in Federal Court
Nadrich & Cohen, LLP reports that three Pradaxa side effects lawsuits have been filed in federal courts across the country.
Los Angeles, CA, March 7, 2012 – National law firm Nadrich & Cohen, LLP has learned that three Pradaxa side effects lawsuits have been filed against Boehringer Ingelheim, the drug’s manufacturer. The cases were filed in federal district courts located in Tennessee, Kentucky and Louisiana and it’s believed they are the…
More Releases for FDA
Exosomes Pipeline Dynamics 2024: FDA Approvals, Therapeutic Advances, Latest FDA …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Exosomes pipeline constitutes 70+ key companies continuously working towards developing 75+ Exosomes treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Exosomes Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/exosomes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Exosomes Market.
The Exosomes Pipeline report embraces in-depth commercial and clinical…
Dengue Pipeline Drugs, FDA Approvals, and Companies 2024
DelveInsight's, "Dengue- Pipeline Insight 2024" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Dengue pipeline landscape. It covers the Dengue pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Dengue Research. Learn more about our innovative…
DreaMed receives 5th FDA Clearance
TEL AVIV, Israel: DreaMed Diabetes LTD. ("DreaMed" or the "Company"), developer of the endo.digital Clinical Decision Support System announced today that it has received its 5th U.S Food and Drug Administration (FDA) clearance that expands the scope of AI enhanced treatment recommendations to patients on fixed meal insulin regimens. endo.digital is the first decision support system that has been cleared to assist healthcare providers in the management of diabetes…
Fully Differential Amplifier (FDA) Market Shows Strong Expansion |
The most recent report published by Market Research Inc. indicates that the Fully Differential Amplifier (FDA) Market is likely to accelerate significantly in the next few years. Specialists have studied market drivers, restraints, risks and prospects in the global market. The Fully Differential Amplifier (FDA) Market report shows the likely direction of the market in the coming years along with its assessments. By analyzing the competitive landscape, the authors of…
St. Louis-based Air Cleaner Earns FDA Clearance
Micron Pure develops tech powering CerroZone, a Berkshire Hathaway and
Marmon Holdings Company.
Chesterfield, Missouri, July 21, 2022. Micron Pure is pleased to announce that its patented ozone technology recently received Federal Drug Administration (FDA) 510(k) Class II clearance for the CerroZone Mobile device as a recirculating air cleaner for eliminating airborne Viruses and Bacteria.
Micron Pure has licensed the technology to Marmon Holdings, a Berkshire Hathaway Company, who will be selling Air…
FDA SETS A NEW GOAL FOR SODIUM REDUCTION
The U.S. Food and Drug Administration released voluntary short-term (2,5 year) sodium reduction guidelines for the food industry on October 14, 2021. The new guidelines include sodium reduction targets for 163 categories of commercially processed, packaged, and restaurant foods. The FDA aims to address the excessive intake of sodium among Americans and promote better public health.
The new sodium reduction guidelines will affect food manufacturers, chain restaurants, and foodservice operators. According…